KRAS and neoplasm: These data suggest that while loss of the wild-type copy of Kras in an aggressive Kras mutant-driven model of intestinal cancer can drive accelerated tumour initiation, it does not endow tumours with increased invasion or aggression, indeed these features appear suppressed.